What is the history of Endometrial cancer?

Endometrial cancer, a malignancy arising from the lining of the uterus, was first clinically described in the 19th century, with early anatomical studies by physicians like Récamier helping to differentiate it from other uterine growths. Over the last 150 years, our understanding of endometrial cancer has evolved from simple surgical observation to a sophisticated, molecularly-driven discipline that now utilizes genetic subtyping to personalize patient care.

How was endometrial cancer first identified?

In the early 1800s, physicians struggled to distinguish between benign fibroids and malignant uterine tumors. Joseph Récamier is often credited with early advancements in uterine diagnostics, such as the use of the curette in 1843, which allowed for the first tissue-based diagnoses of endometrial cancer. Before this, diagnosis relied largely on autopsy findings or advanced, visible disease.

How has our understanding of the disease evolved?

For much of the 20th century, endometrial cancer was viewed as a singular, hormone-dependent condition. However, medical researchers eventually identified two distinct types: Type I, which is estrogen-dependent and typically has a better prognosis, and Type II, which is more aggressive and independent of hormonal influence. Today, the Cancer Genome Atlas (TCGA) has further redefined endometrial cancer into four molecular groups, allowing for precision medicine approaches that were unimaginable a few decades ago.

What are the major milestones in treatment?

The management of endometrial cancer has shifted significantly due to technological and surgical innovation:

• 1900s: Radical hysterectomy becomes the gold standard for surgical intervention.


• 1970s: The introduction of adjuvant radiation therapy significantly improved survival rates in high-risk patients.


• 1990s: Minimally invasive surgery, including laparoscopic and robotic-assisted techniques, reduced recovery times and surgical complications.


• 2010s-Present: The integration of immunotherapy and targeted molecular therapies for advanced cases.

How have misconceptions about endometrial cancer changed?

Historically, endometrial cancer was often misattributed solely to lifestyle factors or "reproductive history," leading to victim-blaming. Modern medical literature has corrected these misconceptions by highlighting the critical role of genetic predispositions, such as Lynch Syndrome, which accounts for approximately 3-5% of all cases. Currently, 31 members of our DiseaseMaps community are actively sharing their experiences, helping to reduce the stigma associated with the diagnosis.

Next steps

• Consult a gynecologic oncologist to discuss your specific molecular subtype.


• Speak with a genetic counselor if you have a family history of colorectal or uterine cancers.


• Join our DiseaseMaps community to connect with others who have navigated this diagnosis.

Medical disclaimer: This information is for educational purposes and should not replace professional medical advice, diagnosis, or treatment.

References

• NIH National Cancer Institute (NCI) - Endometrial Cancer Overview


• Orphanet - Rare Diseases Database


• The Cancer Genome Atlas (TCGA) Research Network - Integrated Genomic Characterization of Endometrial Carcinoma


• Foundation for Women's Cancer (FWC)